Reata Pharmaceuticals Inc.’s bardoxolone methyl continued its rise from the ashes, as the antioxidant inflammation modulator (AIM) showed kidney function benefit in the fourth and final chronic kidney disease (CKD) indication studied in the Phase II proof-of-concept PHOENIX study.
The firm terminated a 2,000-patient, Phase III study of bardoxolone in 2012 due to a high rate of adverse events...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)